WINNIPEG, Manitoba (November 20, 2012) - Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce it has received Notification Number "NN.W33A" from the Low Risk Veterinary Health Products (LRVHPs) program for the marketing of StrixNB in Canada. With the issuance of a notification number, the Company has cleared the final requirements and moves closer to market launch of StrixNB for the pet market in Canada.
North American Compendiums, in cooperation with Health Canada and the Canadian Animal Health Institute, has developed a notification program for low-risk veterinary health products used in cats, dogs, and horses. This program is an interim measure intended to assess the effectiveness of a streamlined approach to oversee LRVHPs with a view to informing the development of a new veterinary drugs regulatory framework.
"We are very pleased to obtain the LRVHP notification number and this combined with the excellent results from our veterinary clinic testing clears the path to launching our first product into the marketplace "stated Mr. Gord Froehlich, President and CEO of Kane Biotech. "We are in the process of assigning product manufacturing and distribution for the commercialization of StrixNB".
StrixNB is a patent pending unique oral care product that has synergistic antimicrobial and antibiofilm activity against bacteria associated with dental plaque, periodontal disease and halitosis (bad breath). This product inhibits plaque (biofilm) formation and also kills bacteria embedded in preformed dental plaque.